Skip to content

EV / sales at other companies

Abbott logo
AbbottABT
4.6×-1.0×
Boston Scientific logo
Boston ScientificBSX
-1.5×
Medtronic logo
MedtronicMDT
3.6×-0.4×
Stryker logo
StrykerSYK
5.4×-1.3×
Johnson & Johnson logo
Johnson & JohnsonJNJ
6.5×+1.8×
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
2.1×-0.3×

Other financials

Income statement

See full
Revenue$1.6B+16.7%
Gross profit$1.3B+15.7%
Operating income$477.6M+21.0%
Net income$380.7M+6.3%
EPS (diluted)$0.66+8.2%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation

See full
Market cap$49.91B+8.7%
Enterprise value$48.17B+11.0%
P/E45.5×+34.6×
P/S7.9×-0.4×

Profitability

See full
Gross margin77.9%-1.6pp
Operating margin21.4%-4.4pp
Net margin17.4%-58.3pp

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Where this comes from

Calculated from Edwards Lifesciences’s reported figures.

Based on the most recent quarter.

The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edwards Lifesciences's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edwards Lifesciences's EV / sales?
Edwards Lifesciences (EW) reported EV / sales of 7× in Q1 2026.
How has Edwards Lifesciences's EV / sales changed year-over-year?
Edwards Lifesciences's EV / sales decreased by 2.7% year-over-year, from 7.2× to 7×.
What is the long-term trend for Edwards Lifesciences's EV / sales?
Over 4 years (2021 to 2025), Edwards Lifesciences's EV / sales has grown at a -13.7% compound annual growth rate (CAGR), from 53.7× to 29.8×.
What does EV / sales mean?
What the whole business costs relative to its annual sales.
How do you interpret EV / sales?
A fallback valuation gauge for pre-profit or cyclical firms. Like P/S, only comparable across similar-margin businesses, but it accounts for debt and cash unlike P/S.
How does EV / sales compare across companies?
Compare within a margin cohort; the debt-and-cash adjustment makes it cleaner than P/S for leveraged firms.